Table 4.
Treatment with mepolizumab in patients with ABPA and asthma.
| Pre-treatment clinical variables | Post-treatment clinical variables | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study ID | Type of study | Sample | Gender | Age | Previous biologic treatment | Absolute eosinophil count (cell/µL) | Total IgE (IU/mL) | FEV1 (%predicted or L) | Frequency of acute exacerbations or asthma control test | Antifungal treatment | Follow-up time | Total eosinophil count (cell/µL) | Total IgE (IU/mL) | FEV1 (%predicted or L) | Frequency of acute exacerbations or Asthma control test | Systemic steroids | Antifungal treatment |
| Soeda et al.23 | Case report | 2 | F | 54 | No | 1365 | 2145 | 2.39 L | 21 | No | 6 mo | 73 | No change | 2.48 L | 25 | N.A. | No |
| F | 61 | No | 1856 | 162 | NI | 24 | No | 2 mo | 32 | No change | NI | 24 | N.A. | No | |||
| Hirota et al.24 | Case report | 1 | F | 56 | Omalizumab (94 wk) | 1500 | 2421 | 1.42 L (62%) | NI | Itraconazole | 14 mo | 0 | 362 | No change | Improved | Discontinued | NI |
| Tsubouch et al.28 | Case report | 1 | F | 60 | No | 560 | 8327 | 1.59 l (79.3%) | NI | Itraconazole | 5 mo | 20 | 2025 | 1.49 L (80%) | Improved | Dose decrease - 5 mg/day | Itraconazole 200 mg/day |
| Oda, et al.12 | Case report | 1 | M | 33 | No | 6370 | 1505 | 2.36 L | 5 | Itraconazole - 8 mo | 9 mo | 64 (2 mo) | NI | 3.16 L (71%) (6 mo) | 25 (2 mo) | Dose decrease - 2.5 mg/day | NI |
| Terashima et al.26 | Case report | 1 | F | 64 | No | 3017 | 3400 | 1.01 L | 18 | Itraconazole - 3 yr | 2 mo | 174 | No change | 1.28 L | 24 | Discontinued | NI |
| Patel et al.13 | Conference abstract - case series | 4 | NI | NI | Omalizumab | 725 (360–1080)b | 997 (134–1730)b | 52% (26–72%)b | NI | NI | NI | NI | NI | NI | Improved | Discontinued | NI |
| Kubena et al.27 | Case report | 1 | F | 58 | Omalizumab | 1310 | 2242 | NI | 3–4/Yearc | Itraconazole | NI | 100 | 720 | Improved | Improved | Dose decrease - 2.5 mg/day | NI |
| Altman et al.28 | Case report | 1 | F | 58 | Omalizumab | 1100 | 1730 | 0.74 L | NI | Itraconazole - 3 mo Voriconazole - 4 mo | 5 mo | 0 | 298 | 0.66 L | Improved | Discontinued | No |
| Florence et al.29 | Case series | 20 | M9:F11 | 63a | Omalizumab | 660 (438–980)b | NI | 1.50 L (1.08–2.11)b | 3/year (2–4.5)cb/10 (8–13)bd | Itraconazole - 1 Patient | 6 mo | 54 (25–115)b | NI | 1.84 L (1.14–2.37)b | 0/year (0–1)cb/19 (10–21)bd | Dose decrease and discotinued | NI |
a
Mean (SD/range).
b
Median (range).
c
Frequency of acute exacerbations.
d
Asthma control test.
ABPA, allergic bronchopulmonary aspergillosis.